R. Morant

1.7k total citations
54 papers, 1.3k citations indexed

About

R. Morant is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, R. Morant has authored 54 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in R. Morant's work include Gastric Cancer Management and Outcomes (8 papers), Cancer Treatment and Pharmacology (7 papers) and Lung Cancer Treatments and Mutations (6 papers). R. Morant is often cited by papers focused on Gastric Cancer Management and Outcomes (8 papers), Cancer Treatment and Pharmacology (7 papers) and Lung Cancer Treatments and Mutations (6 papers). R. Morant collaborates with scholars based in Switzerland, United Kingdom and Italy. R. Morant's co-authors include Markus Borner, Aron Goldhirsch, M. Castiglione, A. Roth, Rudolf Maibach, Beat Thürlimann, Martin F. Fey, Nicola Fazio, H.-J. Senn and Olivia Pagani and has published in prestigious journals such as Journal of Clinical Oncology, The EMBO Journal and British Journal of Cancer.

In The Last Decade

R. Morant

51 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Morant Switzerland 22 722 494 243 197 185 54 1.3k
M. Venturini Italy 25 1.3k 1.7× 281 0.6× 156 0.6× 154 0.8× 246 1.3× 87 1.9k
Phuong K. Morrow United States 24 1.0k 1.5× 396 0.8× 525 2.2× 198 1.0× 112 0.6× 65 1.8k
Giuseppina Catalano Italy 28 1.4k 1.9× 835 1.7× 268 1.1× 294 1.5× 377 2.0× 72 2.2k
R. Cellerino Italy 25 1.1k 1.5× 905 1.8× 338 1.4× 54 0.3× 276 1.5× 96 2.0k
Judith A.M. Wessels Netherlands 23 338 0.5× 248 0.5× 446 1.8× 406 2.1× 178 1.0× 43 2.0k
Olivier Huillard France 20 540 0.7× 438 0.9× 311 1.3× 84 0.4× 134 0.7× 84 1.4k
Aart van Bochove Netherlands 16 1.3k 1.7× 464 0.9× 126 0.5× 62 0.3× 235 1.3× 32 1.6k
James B. Gerstner United States 18 1.6k 2.2× 544 1.1× 316 1.3× 57 0.3× 305 1.6× 29 2.1k
Tomoo Tajima Japan 23 1.2k 1.6× 557 1.1× 358 1.5× 58 0.3× 584 3.2× 153 2.2k
Hugh L. Davis United States 19 517 0.7× 276 0.6× 144 0.6× 59 0.3× 221 1.2× 46 1.1k

Countries citing papers authored by R. Morant

Since Specialization
Citations

This map shows the geographic impact of R. Morant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Morant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Morant more than expected).

Fields of papers citing papers by R. Morant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Morant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Morant. The network helps show where R. Morant may publish in the future.

Co-authorship network of co-authors of R. Morant

This figure shows the co-authorship network connecting the top 25 collaborators of R. Morant. A scholar is included among the top collaborators of R. Morant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Morant. R. Morant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Senn, H.-J. & R. Morant. (2008). Chemoprevention of breast and prostate cancers: where do we stand?. Annals of Oncology. 19. vii234–vii237. 5 indexed citations
2.
Glaus, A, Beat Thürlimann, Thomas Ruhstaller, et al.. (2006). Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Annals of Oncology. 17(5). 801–806. 70 indexed citations
3.
Cutsem, Eric Van, Luc Dirix, J-L. van Laethem, et al.. (2005). Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. British Journal of Cancer. 92(6). 1055–1062. 35 indexed citations
4.
Fürstenberger, G., R. Morant, & Hans-Jörg Senn. (2003). Insulin-Like Growth Factors and Breast Cancer. Oncology Research and Treatment. 26(3). 290–294. 29 indexed citations
5.
Morant, R., S.‐F. Hsu Schmitz, J. Bernhard, et al.. (2002). Vinorelbine in androgen-independent metastatic prostatic carcinoma—a phase II study. European Journal of Cancer. 38(12). 1626–1632. 25 indexed citations
6.
7.
Morant, R.. (2001). Neoadjuvant and Adjuvant Chemotherapy of Locally Advanced Stomach Cancer. Oncology Research and Treatment. 24(2). 116–121. 6 indexed citations
8.
Sessa, Cristiana, J. Wanders, M. Roelvink, et al.. (2000). Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: A study of the EORTC Early Clinical Studies Group (ECSG). Annals of Oncology. 11(2). 207–210. 16 indexed citations
9.
Bernhard, J., Monica Castiglione‐Gertsch, S.‐F. Hsu Schmitz, et al.. (1999). Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. European Journal of Cancer. 35(6). 913–920. 17 indexed citations
10.
Thatcher, Nicholas, David Bell, W P Steward, et al.. (1999). Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. British Journal of Cancer. 80(3-4). 396–402. 102 indexed citations
11.
Borner, M., M. Castiglione, M. Bacchi, et al.. (1998). The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: Results of a phase III trial. Annals of Oncology. 9(5). 535–541. 45 indexed citations
12.
13.
Ludwig, Heinz, Asaf Cohen, Aaron Polliack, et al.. (1995). Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies. Annals of Oncology. 6(5). 467–476. 69 indexed citations
14.
15.
Morant, R., et al.. (1994). Clinical Assessment of the New Tumor Marker TPS. Oncology Research and Treatment. 17(3). 270–276. 1 indexed citations
16.
17.
Stiefel, Friedrich, et al.. (1993). Attitudes of Swiss physicians in prescribing opiates for cancer pain. Supportive Care in Cancer. 1(5). 259–262. 12 indexed citations
18.
Stahel, R., H. Lacroix, Sculier Jp, et al.. (1992). Phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancer. Annals of Oncology. 3(4). 319–320. 18 indexed citations
19.
Morant, R., et al.. (1991). [Why do cancer patients use alternative medicine?].. PubMed. 121(27-28). 1029–34. 40 indexed citations
20.
Christen, R D, R. Morant, Jakob Schneider, Rolf Jenni, & J Fehr. (1989). Progressive dilated cardiomyopathy in a patient with longstanding and complete prednisone-induced hematological remission of idiopathic hypereosinophilic syndrome. Journal of Molecular Medicine. 67(6). 358–365. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Venturini Breakdown of academic impact, for papers by Phuong K. Morrow Breakdown of academic impact, for papers by Giuseppina Catalano Breakdown of academic impact, for papers by R. Cellerino Breakdown of academic impact, for papers by Judith A.M. Wessels Breakdown of academic impact, for papers by Olivier Huillard Breakdown of academic impact, for papers by Aart van Bochove Breakdown of academic impact, for papers by James B. Gerstner Breakdown of academic impact, for papers by Tomoo Tajima Breakdown of academic impact, for papers by Hugh L. Davis
Rankless by CCL
2026